Stockreport

Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer's Disease [Yahoo! Finance]

Annovis Bio, Inc.  (ANVS) 
PDF Improvement in cognition measured by ADAS-Cog 11 at three months is 3.3 points as compared to 0.3 for placebo, consistent with our previous Phase II AD/PD and Discover [Read more]